Eileen O Reilly, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support from Agios, Arcus, AstraZeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva and consulting fees from Adicet, Alnylam, AstraZeneca, Autem, Bayer, BeiGene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Lilly, Merck, Nerviano, QED, Rafael, Redhill, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva.
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP
Associate Director of Clinical Research
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom
Naureen Starling, MD, FRCP, has disclosed that she has received consulting fees from Amgen, GSK, Lilly, MSD, Novartis, Pierre Fabre, and Servier.